



Commonwealth of Massachusetts  
**MassHealth Drug Utilization Review Program**  
 P.O. Box 2586, Worcester, MA 01613-2586  
 Fax: (877) 208-7428 Phone: (800) 745-7318

## Narcolepsy and Miscellaneous Sleep Disorder Therapy Agents Prior Authorization Request

MassHealth reviews requests for prior authorization (PA) on the basis of medical necessity only. If MassHealth approves the request, payment is still subject to all general conditions of MassHealth, including current member eligibility, other insurance, and program restrictions. MassHealth will notify the requesting provider and member of its decision. Keep a copy of this form for your records. If faxing this form, please use black ink.

Additional information about these agents, including PA requirements and preferred products, can be found within the MassHealth Drug List at [www.mass.gov/druglist](http://www.mass.gov/druglist).

### Member information

Last name \_\_\_\_\_ First name \_\_\_\_\_ MI \_\_\_\_\_  
 MassHealth member ID # \_\_\_\_\_ Date of birth \_\_\_\_\_  
 Gender (Check one.)  F  M Member's place of residence  home  nursing facility

### Medication information

#### Medication requested

- |   |   |  |
|---|---|--|
| <input type="checkbox"/> armodafinil > 1 unit/day           | <input type="checkbox"/> modafinil 200 mg > 2 units/day | <input type="checkbox"/> Xywav (calcium oxybate/<br>magnesium oxybate/potassium<br>oxybate/sodium oxybate) |
| <input type="checkbox"/> Hetlioz (tasimelteon)              | <input type="checkbox"/> Sunosi (solriamfetol)          |  |
| <input type="checkbox"/> modafinil 100 mg > 1.5<br>unit/day | <input type="checkbox"/> Wakix (pitolisant)             |  |
|   | <input type="checkbox"/> Xyrem (sodium oxybate)         |  |

Dose and frequency of medication requested \_\_\_\_\_

#### Indication (Check all that apply.)

- |   |  |
|---|--|
| <input type="checkbox"/> Cataplexy associated with narcolepsy                             | <input type="checkbox"/> EDS associated with obstructive sleep apnea (OSA) |
| <input type="checkbox"/> Idiopathic hypersomnia   | <input type="checkbox"/> Non-24-hour sleep-wake disorder                   |
| <input type="checkbox"/> Excessive daytime sleepiness (EDS)<br>associated with narcolepsy | <input type="checkbox"/> Smith-Magenis Syndrome (SMS)                      |
|   | <input type="checkbox"/> Other (Please specify.) _____                     |

Please indicate prescriber specialty below.

Neurology  Sleep  Other (Please specify.) \_\_\_\_\_

If prescriber is not a specialist, please attach consult notes from a specialist.

### Section I. Please complete for Sunosi, Wakix, Xyrem, and Xywav for the diagnosis of narcolepsy. Please also complete Section IV or V below as appropriate.

Has the member had a sleep study (polysomnogram or multiple sleep latency test) that diagnosed narcolepsy?

- Yes. Please include medical records with submission.  
 No. Please explain why this member has not had a sleep study or why treatment is required when sleep study did not document narcolepsy. \_\_\_\_\_

### Section II. Please complete for Sunosi for the diagnosis of EDS associated with OSA.

1. Has the member had a sleep study (polysomnogram) that diagnosed obstructive sleep apnea?

- Yes. Please include medical records with submission.  No

2. Is the member utilizing CPAP/BiPAP, an oral appliance, or has undergone successful surgical treatment for OSA?
- Yes. Please include medical records with submission.
- No. Please explain why this member is not utilizing CPAP/BiPAP, an oral appliance, or surgical treatment for OSA. \_\_\_\_\_
3. For Sunosi, has the member tried modafinil or armodafinil for the treatment of this condition?\*
- Yes. Please list the drug name, dates of trials and outcomes In Section VII below.
- No. Please describe clinical rationale why modafinil or armodafinil is not appropriate for this member.
- \_\_\_\_\_

---

**Section III. Please complete for requests for the diagnosis of non-24-hour sleep-wake disorder and SMS.**

For the diagnosis of non-24-hour sleep-wake disorder, please complete questions 1 and 2. For SMS, complete questions 1 and 3.

1. Has the member tried melatonin for the treatment of this condition?\*
- Yes. Please list the drug name, dates of trials and outcomes in Section VII below.
- No. Please describe clinical rationale why melatonin is not appropriate for this member.
- \_\_\_\_\_
2. Is the member totally blind?  Yes  No
3. For Hetlioz suspension, please provide medical necessity for use over the capsule formulation.
- \_\_\_\_\_

---

**Section IV. Please also complete for requests for Sunosi, Wakix, Xyrem, and Xywav for a diagnosis of EDS associated with narcolepsy. Please complete Section I above as appropriate.**

1. Has the member tried modafinil or armodafinil for the treatment of this condition?\*
- Yes. Please list the drug name, dates of trials and outcomes in Section VII below.
- No. Please describe clinical rationale why modafinil or armodafinil is not appropriate for this member.
- \_\_\_\_\_
2. Has the member tried a cerebral stimulant for the treatment of this condition?\*
- Yes. Please list the drug name, dates of trials and outcomes in Section VII below.
- No. Please describe clinical rationale why a cerebral stimulant is not appropriate for this member.
- \_\_\_\_\_
3. For Sunosi, will the requested medication be used as monotherapy?
- Yes
- No. Please describe treatment plan including clinical rationale for combination therapy.
- \_\_\_\_\_
4. For Wakix, has the member tried Sunosi for the treatment of this condition?\*
- Yes. Please list the drug name, dates of trials and outcomes in Section VII below.
- No. Please describe the clinical rationale why Sunosi is not appropriate for this member.
- \_\_\_\_\_
5. For Wakix, has the member tried Xyrem for the treatment of this condition?\*
- Yes. Please list the drug name, dates of trials and outcomes in Section VII below.
- No. Please describe the clinical rationale why Xyrem is not appropriate for this member.
- \_\_\_\_\_
6. For Xywav, is there medical necessity for use instead of Xyrem for the treatment of this condition?\*
- Yes. Please explain. \_\_\_\_\_
- No

---

**Section V. Please also complete for requests for Wakix, Xyrem, and Xywav for a diagnosis of cataplexy associated with narcolepsy. Please complete Section I above as appropriate.**

1. Has the member tried atomoxetine, a selective serotonin reuptake inhibitor (SSRI), tricyclic antidepressant (TCA), or venlafaxine for the treatment of this condition?\*
- Yes. Please list the drug name, dates of trials and outcomes in Section VII below.
- No. Please describe clinical rationale why SSRIs, TCAs, and venlafaxine are not appropriate for this member. \_\_\_\_\_
2. For Wakix, has the member tried Xyrem or Xywav for the treatment of this condition?\*
- Yes. Please list the drug name, dates of trials and outcomes in Section VII below.
- No. Please describe the clinical rationale why Xyrem and Xywav are not appropriate for this member. \_\_\_\_\_
3. For Xywav, is there medical necessity for use instead of Xyrem for the treatment of this condition?\*
- Yes. Please explain. \_\_\_\_\_
- No

---

**Section VI. Please also complete for requests for Xyrem and Xywav for a diagnosis of idiopathic hypersomnia.**

1. Has the member had a polysomnogram ruling out other causes of hypersomnia?
- Yes. Please include medical records with submission.
- No. Please explain why not. \_\_\_\_\_
2. Has the member had a multiple sleep latency test?
- Yes. Please include medical records with submission.
- No. Please explain why not. \_\_\_\_\_
3. Does the member have hypersomnia due to another medical, behavioral, or psychiatric disorder?
- Yes. Please explain. \_\_\_\_\_
- No.
4. Please attach a current medication list. Is the member currently utilizing a drug that can cause excessive daytime sleepiness?
- Yes. Please explain. \_\_\_\_\_
- No.
5. Has the member tried a cerebral stimulant for the treatment of this condition?\*
- Yes. Please list the drug name, dates of trials and outcomes in Section VII below.
- No. Please describe clinical rationale why a cerebral stimulant is not appropriate for this member. \_\_\_\_\_
6. Has the member tried modafinil or armodafinil for the treatment of this condition?\*
- Yes. Please list the drug name, dates of trials and outcomes in Section VII below.
- No. Please describe clinical rationale why modafinil or armodafinil is not appropriate for this member. \_\_\_\_\_
7. For Xywav, is there medical necessity for use instead of Xyrem for the treatment of this condition?\*
- Yes. Please explain. \_\_\_\_\_
- No

---

**Section VII. Please complete for all requests as needed.**

Please provide the following information regarding previous trials.\*

Drug \_\_\_\_\_ Dates of use \_\_\_\_\_

Adverse reaction  Inadequate response  Other

Briefly describe details of adverse reaction, inadequate response, or other.

Drug \_\_\_\_\_ Dates of use \_\_\_\_\_  
 Adverse reaction  Inadequate response  Other  
Briefly describe details of adverse reaction, inadequate response, or other.

Drug \_\_\_\_\_ Dates of use \_\_\_\_\_  
 Adverse reaction  Inadequate response  Other  
Briefly describe details of adverse reaction, inadequate response, or other.

---

**Section VIII. Please complete for requests for quantities above quantity limits.**

Please describe the clinical rationale for exceeding the quantity limit. For armodafinil and modafinil, attach medical records documenting titration to doses exceeding the FDA-recommendations.

---

**Section IX. Please complete for all requests for non-preferred drug products if one or more preferred drug products have been designated for this class of drugs.**

If one or more preferred drug products have been designated for this class of drugs, and if you are requesting PA for a non-preferred drug product, please provide medical necessity for prescribing the non-preferred drug product rather than the preferred drug product.

*\* Please attach a letter documenting additional trials as necessary.*

---

**Prescriber information**

Last name\* \_\_\_\_\_ First name\* \_\_\_\_\_ MI \_\_\_\_\_  
NPI\* \_\_\_\_\_ Individual MH Provider ID \_\_\_\_\_  
DEA No. \_\_\_\_\_ Office Contact Name \_\_\_\_\_  
Address \_\_\_\_\_ City \_\_\_\_\_ State \_\_\_\_\_ Zip \_\_\_\_\_  
E-mail address \_\_\_\_\_  
Telephone No.\* \_\_\_\_\_ Fax No.\* \_\_\_\_\_

*\* Required*

---

**Prescribing provider's attestation, signature, and date**

I certify under the pains and penalties of perjury that I am the prescribing provider identified in the Prescriber information section of this form. Any attached statement on my letterhead has been reviewed and signed by me. I certify that the medical necessity information (per 130 CMR 450.204) on this form is true, accurate, and complete, to the best of my knowledge. I understand that I may be subject to civil penalties or criminal prosecution for any falsification, omission, or concealment of any material fact contained herein.

Prescribing provider's signature (Signature and date stamps, or the signature of anyone other than the provider, are not acceptable.)

**Signature required** \_\_\_\_\_

Printed name of prescribing provider \_\_\_\_\_ Date \_\_\_\_\_